Plain-English translation of NCT05776212 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how calcium deposits form in the hearts of people with transthyretin amyloidosis (a rare condition where abnormal proteins damage the heart). They want to understand how a new medication called Tafamidis works to help patients, and they're using a special type of heart imaging called PET scans to track changes over time.
This medication has been shown to help patients live longer and reduce hospital stays, but doctors don't fully understand how it works or whether it actually reduces the harmful calcium buildup in the heart. This study will help answer those important questions.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or imaging center for special heart scans, including PET imaging and possibly cardiac MRI scans. Some participants will also be tracked over time to see how their heart changes with the new medication. The researchers have tried to minimize the burden on patients while still getting the information they need.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
Netherlands
Collaborators
British Heart Foundation, Netherlands Heart Foundation
Enrollment target
~140 participants
Started
August 2021
Primary completion
September 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Riemer Slart, MD PhD
Centre of Cardiovascular Science
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.